Acute Myeloid Leukemia Therapeutics Market

Acute Myeloid Leukemia Therapeutics Market Size, Market Forecast and Outlook by Fact.MR

• The acute myeloid leukemia therapeutics market was valued at USD 3.8 billion in 2025.
• Demand is expected to increase from USD 4.2 billion in 2026 to USD 10.1 billion by 2036.
• The market is forecast to record 9.2% CAGR during 2026 to 2036 as targeted therapies and relapse-focused treatments gain wider clinical use.
• Acute myeloid leukemia therapeutics demand is becoming more genomics-led.
• NCI’s AML treatment PDQ states that treatment options include chemotherapy, stem cell transplant, maintenance therapy, and other drug therapy.
• This supports a treatment landscape that combines older cytotoxic therapy with newer targeted approaches.

Summary of the Acute Myeloid Leukemia Therapeutics Market

• Demand Drivers in the Market
  • Mutation-Led Therapy: Hematologists use molecular results to select targeted AML drugs.
  • Older Patient Need: Lower-intensity regimens support patients who cannot tolerate intensive induction.
  • Relapse Treatment: New oral targeted drugs are expanding options for refractory and recurrent AML.
• Key Segments Analyzed
  • By Drug Class: Targeted therapies are expected to hold 36.0% share in 2026 because mutation-defined AML is reshaping treatment choice.
  • By Disease Type: Newly diagnosed AML leads because first-line treatment creates the main therapy volume. The segment is likely to account for 48.0% share in 2026.
  • By Route of Administration: Intravenous therapy is projected to hold 52.0% share in 2026 because induction and hospital-based regimens need IV delivery.
  • By End User: Hospitals lead as AML diagnosis and induction therapy usually begin in inpatient oncology units. The segment is anticipated to capture 55.0% share in 2026.
  • By Sales Channel: Hospital pharmacies are expected to hold 49.0% share in 2026 because most acute AML regimens begin under hospital supervision.
  • By Geography: India is projected to record 11.8% CAGR through 2036 as cancer center access and molecular testing expand.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, states, “Acute myeloid leukemia therapeutics are becoming more mutation-specific and patient-risk driven. We see demand rising for oral targeted drugs and lower-intensity combinations.”
• Strategic Implications
  • Molecular Access: Cancer centers should expand mutation testing before final therapy selection so clinicians can match AML patients with targeted treatment options.
  • Therapy Sequencing: Hematologists need clear pathways for induction and maintenance treatment to guide therapy decisions across changing AML disease stages safely.
  • Pharmacy Readiness: Hospitals need safe handling and monitoring protocols for high-risk AML drugs so pharmacy staff can manage toxicity and dosing risks.

The market is moving from broad chemotherapy-only treatment toward patient-specific therapy selection. Older patients often need lower-intensity treatment. Relapsed and refractory patients need new oral options and targeted therapies. Mutation testing is becoming more important because drug selection can depend on FLT3 or NPM1 status.

India is projected to record 11.8% CAGR by 2036 as cancer center access and molecular testing expand. China is likely to post 10.9% CAGR through 2036 as hematology capacity and targeted therapy access improve. The United States is expected to register 8.7% CAGR from 2026 to 2036 as approved targeted drugs and specialty pharmacy access sustain demand. Germany is forecast to advance at 7.9% CAGR by 2036 because advanced hematology care supports protocol-led therapy use. Japan is set to record 7.4% CAGR through 2036 as aging patients and hospital-based hematology care sustain treatment demand.

Segmental Analysis

Acute Myeloid Leukemia Therapeutics Market Analysis by Drug Class

Targeted therapies are expected to hold 36.0% share in 2026 because mutation-defined AML is reshaping treatment choice. FLT3 and NPM1-directed drugs are expanding the precision treatment base. Chemotherapy agents still support induction and consolidation in eligible patients. Hypomethylating agents remain important for older patients and lower-intensity regimens. BCL-2 inhibitors support combination treatment in newly diagnosed AML patients who cannot tolerate intensive induction.

• Targeted Therapy: Mutation-directed agents help clinicians treat AML groups with clearer genetic treatment markers.
• Lower-Intensity Use: Hypomethylating combinations support older patients who cannot tolerate aggressive induction therapy.
• Chemotherapy Base: Cytotoxic regimens remain important for eligible patients pursuing curative-intent treatment.

Acute Myeloid Leukemia Therapeutics Market Analysis by Disease Type

Newly diagnosed AML leads because first-line treatment creates the main therapy volume. Patients often start therapy quickly after diagnosis and risk assessment. The segment is likely to account for 48.0% share in 2026 as induction and lower-intensity regimens drive initial drug demand. Relapsed AML needs targeted options and salvage therapy. Refractory AML creates demand for newer drug classes and clinical review. Secondary AML is harder to treat and often needs adjusted regimens. Mutation-defined AML is gaining value because molecular status guides drug selection.

• First-Line Demand: Newly diagnosed patients create early treatment volume through induction and lower-intensity regimens.
• Relapse Need: Recurrent AML requires targeted drugs and careful reassessment of prior therapy response.
• Mutation Groups: Genetic subtypes help clinicians match patients with newer precision treatment options.

Acute Myeloid Leukemia Therapeutics Market Analysis by Route of Administration

Intravenous therapy is likely to hold 52.0% share in 2026 because induction and hospital-based regimens need IV delivery. Oxford Haematology’s 2025 AML induction protocol lists daunorubicin by IV route on days 1 to 3 and cytarabine by continuous IV infusion on days 1 to 7 [2]. Cytarabine and several supportive medicines are commonly used under hospital monitoring. Oral therapy is rising as targeted drugs and maintenance approaches expand. Subcutaneous therapy supports selected hypomethylating treatment schedules. 

• IV Treatment: Hospital-based regimens use intravenous drugs for induction and high-intensity therapy cycles.
• Oral Expansion: Targeted tablets improve outpatient flexibility for selected relapsed and mutation-defined AML patients.
• Combination Use: Multi-drug regimens help clinicians match intensity with patient risk and treatment goals.

Acute Myeloid Leukemia Therapeutics Market Analysis by End User

Hospitals lead as AML diagnosis and induction therapy usually begin in inpatient oncology units. Patients often need transfusion support and intensive clinical supervision. The segment is anticipated to capture 55.0% share in 2026 because early AML therapy is medically complex. Cancer centers manage targeted therapy selection and relapse treatment. Hematology clinics support follow-up and oral therapy management. Academic medical centers manage complex trials and transplant-linked care.

• Hospital Start: Inpatient oncology units manage induction therapy and transfusion support.
• Cancer Centers: Specialist sites provide molecular treatment selection and relapse-focused care planning.
• Hematology Clinics: Outpatient teams monitor oral therapy response and adverse effects after discharge.

Acute Myeloid Leukemia Therapeutics Market Analysis by Sales Channel

Hospital pharmacies are expected to hold 49.0% share in 2026 because most acute AML regimens begin under hospital supervision. Oncology pharmacists manage cytotoxic drugs and supportive medicines during treatment cycles. Specialty pharmacies support oral targeted drugs and adherence follow-up. Direct hospital supply serves formulary-controlled oncology products. Retail pharmacies support selected supportive care and oral medicine refills. Tender and public supply channels influence access in government hospitals.

• Hospital Control: Oncology pharmacies manage high-risk AML medicines across inpatient treatment and safety monitoring.
• Specialty Access: Specialty pharmacies support oral targeted therapy delivery and patient adherence services.
• Public Supply: Tender channels influence access to generic chemotherapy and supportive medicines in public hospitals.

Acute Myeloid Leukemia Therapeutics Market Drivers, Restraints, and Opportunities

Targeted drug approvals and molecular treatment selection are the main drivers for AML therapeutics demand. Syndax announced in 2025 that Revuforj received approval for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in adult and pediatric patients one year and older [3]. This approval expands menin inhibitor use in mutation-defined AML.

Toxicity and treatment cost can restrain adoption. AML drugs can cause severe myelosuppression and tumor lysis concerns. Intensive chemotherapy requires inpatient monitoring and strong supportive care. New targeted therapies can face payer review and restricted access in cost-sensitive systems. Molecular testing gaps can limit use of mutation-directed therapy.

Opportunities in the Acute Myeloid Leukemia Therapeutics Market

• Menin Inhibitors: Drug makers can target NPM1-mutated and KMT2A-rearranged relapse settings.
• Oral Targeted Therapy: Specialty pharmacies can support adherence and toxicity monitoring for outpatient treatment.
• Older Patient Care: Lower-intensity regimens can serve patients who cannot receive intensive induction therapy.

Regional Analysis

Based on regional analysis, the acute myeloid leukemia therapeutics market is segmented into North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.

Source: Fact.MR analysis, based on proprietary forecasting model and primary research.

South Asia and East Asia Acute Myeloid Leukemia Therapeutics Market Analysis

South Asia and East Asia demand comes from cancer center expansion and rising access to oncology drugs. India leads the growth outlook because tertiary cancer care and private oncology networks are expanding. China has a large hospital base and improving access to targeted hematology drugs.

• India: India is projected to record 11.8% CAGR through 2036 as cancer center access and molecular testing expand. Large hospitals are adding hematology services and oncology pharmacy capacity. AML treatment demand is rising through better diagnosis and wider private cancer care. Cost limits access to newer targeted drugs outside major cities. Generic chemotherapy remains important in public hospitals.
• China: China has broad tertiary hospital capacity and improving hematology care. Cancer hospitals use chemotherapy and targeted therapies across AML pathways. The country is likely to post 10.9% CAGR by 2036 as targeted therapy access and testing improve. Domestic drug makers can serve price-sensitive segments.

North America Acute Myeloid Leukemia Therapeutics Market Analysis

North America demand is led by the United States because targeted therapy access and specialty pharmacy channels are strong. AML treatment is guided by mutation testing and protocol-led hematology care.

• United States: The United States is expected to register 8.7% CAGR through 2036 as approved targeted drugs and specialty pharmacy access sustain demand. FDA approval of ziftomenib in 2025 added another option for R/R AML with susceptible NPM1 mutation. [4] Payer review and toxicity management will remain important adoption filters.

Western Europe Acute Myeloid Leukemia Therapeutics Market Analysis

Western Europe demand comes from mature hematology care and guideline-led oncology practice. Germany leads the regional view because university hospitals and cancer centers manage complex AML cases.

• Germany: Germany is forecast to advance at 7.9% CAGR over the forecast period because advanced hematology care supports protocol-led therapy use. University hospitals use molecular testing to guide targeted treatment and relapse planning. Older AML patients drive demand for lower-intensity regimens and supportive care. Reimbursement review can slow uptake of newer premium therapies. Clinical trial activity supports access to new drug classes.

East Asia Mature Market View

Japan has an aging population and established hospital-based hematology care. AML treatment demand is steady because older patients often need lower-intensity treatment and careful monitoring. Hospital formulary access and safety data affect targeted therapy uptake.

• Japan: Japan is set to record 7.4% CAGR through 2036 as aging patients and hospital-based hematology care sustain treatment demand. Cancer centers use chemotherapy and targeted drugs across AML pathways. Older patients need therapy choices that balance response and tolerability.

Competitive Aligners for Market Suppliers

The acute myeloid leukemia therapeutics market is served by oncology drug companies with targeted therapy and supportive care portfolios. AbbVie Inc. and Genentech, Roche compete through Venclexta for selected AML treatment needs. Astellas Pharma Inc. supports FLT3 mutated AML care through Xospata. Syndax Pharmaceuticals Inc. competes through Revuforj for specific genetically defined AML cases. Kura Oncology Inc. supports targeted AML treatment development through its menin inhibitor program.

Competitive position depends on mutation coverage and hospital formulary access. Toxicity profile and specialty pharmacy support also influence therapy use. Hematologists need treatment options that match molecular testing results and patient fitness. Drug suppliers must support hospitals with clinical education and patient access programs.

Competition will depend on therapy sequencing and molecular testing access through 2036. AML treatment is becoming more precise. Toxicity management remains central in daily care. Suppliers that connect targeted therapy with testing support and hospital education will gain stronger hematology access.

Key Companies in Acute Myeloid Leukemia Therapeutics Market

• AbbVie Inc.
• Genentech, Roche
• Astellas Pharma Inc.
• Syndax Pharmaceuticals, Inc.
• Kura Oncology, Inc.

Bibliography

• [1] National Cancer Institute. (2025, March 14). Acute myeloid leukemia treatment (PDQ®): Health professional version. National Cancer Institute.
• [2] Oxford Department of Haematology, Myeloid Group. (2025, June). DA (daunorubicin + cytarabine). Oxford Haematology NSSG.
• [3] Syndax Pharmaceuticals, Inc. (2025, October 24). Syndax announces FDA approval of Revuforj® (revumenib) in adult and pediatric patients with relapsed or refractory NPM1 mutated acute myeloid leukemia. Syndax Pharmaceuticals.
• [4] U.S. Food and Drug Administration. (2025, November 13). FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation. U.S. Food and Drug Administration.

This Report Addresses

• Strategic intelligence on acute myeloid leukemia therapeutics demand across drug class, disease type, route, end user, and sales channel.
• Forecast mapping from USD 4.2 billion in 2026 to USD 10.1 billion by 2036.
• Segment analysis covering targeted therapies, newly diagnosed AML, intravenous therapy, hospitals, and hospital pharmacies.
• Regional outlook covering India, China, the United States, Germany, and Japan.
• Competitive analysis of AbbVie Inc., Genentech, Roche, Astellas Pharma Inc., Syndax Pharmaceuticals, Inc., Kura Oncology, Inc.
• Therapy assessment covering chemotherapy, targeted therapy, hypomethylating agents, BCL-2 inhibitors, and supportive care drugs.
• Channel assessment covering hospital pharmacies, specialty pharmacies, direct hospital supply, retail pharmacies, and public supply channels.
• Primary interviews, supplier checks, official source review, and AML treatment workflow validation support the forecast.

Acute Myeloid Leukemia Therapeutics Market Definition

The acute myeloid leukemia therapeutics market covers drugs used to treat AML across newly diagnosed and mutation-defined patient groups. It includes chemotherapy agents and supportive care drugs. The market differs from general leukemia therapy because it focuses on AML-specific treatment pathways.

Acute Myeloid Leukemia Therapeutics Market Inclusions

The scope includes branded and generic AML drugs used in induction and supportive care. It includes venetoclax combinations and cytotoxic chemotherapy. Hospital pharmacy and public supply channels are included.

Acute Myeloid Leukemia Therapeutics Market Exclusions

The scope excludes diagnostics and hospital service fees. It excludes chronic myeloid leukemia drugs unless used in AML pathways. It excludes clinical trial services and companion diagnostic products sold separately from drug therapy.

Acute Myeloid Leukemia Therapeutics Market Research Methodology

• Primary Research
  • Primary research includes interviews with hematologists and oncology pharmacists. It includes input from cancer center formulary committees and hospital oncology supply managers.
• Desk Research
  • Desk research reviews AML treatment references and official drug approval records. It covers prescribing information and public cancer statistics.
• Market-Sizing and Forecasting
  • Forecasting uses drug class demand and disease type mix. Route of administration and channel structure support the market assessment.
• Data Validation and Update Cycle
  • Forecasts are validated through hospital feedback and supplier checks. AML treatment use and specialty pharmacy movement help confirm market direction.